Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
AGT4 + AGZ
- Development stage
- Unknown
- Lead developer
- AHN-GOOK PHARMACEUTICAL
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
AGT4 + AGZ is a combination therapy under investigation for the treatment of primary hypercholesterolemia. The combination consists of two agents, referred to as "AGT4" and "AGZ," administered together in tablet form once daily. The therapy is being evaluated in a multi-center, randomized, double-blind, active-controlled phase 3 clinical trial to assess its efficacy and safety compared to monotherapy with either component. The primary endpoint is the percentage change in LDL-C (low-density lipoprotein cholesterol) from baseline at week 8[1]. Specific details regarding the mechanisms of action or chemical identities of AGT4 and AGZ are not provided in available sources.
Beyond the preview
Go deeper on AGT4 + AGZ.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on AGT4 + AGZ.